It started with an urgent call in 2022.
A client reached out, asking for a favour. Her team needed immediate support to deliver a series of upcoming oncology advisory boards. At the time, Canada was still navigating the challenges of COVID-19, and engaging discussions with healthcare professionals was anything but simple. What was meant to be a one off quickly evolved into something much bigger.
That initial request grew into nearly 20+ oncology-focused advisory boards delivered across Canada, both virtual and in-person at key Oncology meetings such as ASCO, ASCO GU, ASCO GI and CUA. These boards spanned a wide range of formats and advisors, including sessions with medical oncologists, hematologist-oncologists, pathologists, oncology pharmacists, oncology nurses, and even drug access navigators. Each Ad Board required not just logistics, but a deep understanding of the clinical landscape, evolving standards of care, and the nuances of multidisciplinary collaboration.
So why me?
Because oncology expertise matters.
In many cases, my role extends far beyond organizing the advisory board. I often co-chair discussions or moderate the entire session, guiding complex oncology based discussions, probing for the right follow-up questions, and ensuring that insights are both meaningful and actionable. This level of engagement simply isn’t possible without a strong foundation in oncology.
Advisory boards in this space are not just meetings or focus groups, they are strategic, insight-driven exchanges that require credibility, confidence, and clinical fluency.
That’s why I’ve made a deliberate choice: I focus exclusively on oncology advisory boards. It allows me to bring the depth of knowledge, precision, and leadership that these conversations demand and that clients rely on.
